Seeking Alpha

Tesaro joins up with AnaptysBio to develop cancer immunotherapies

  • Tesaro (TSRO) has signed a global licensing deal with privately held AnaptysBio for a portfolio of antibodies that could be used to develop cancer immunotherapies.
  • Tesaro will pay AnaptysBio $17M up front and development costs. For each development project, Tesaro will pay $18M in R&D milestones and $90M related to regulatory progress. AnaptysBio will also receive royalties on any product sales. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector